Fine particulate matter (PM2.5) and ozone (O3) may exert oxidative damage in the nose,
which is hypothesized to
be associated with worsened asthma symptoms. This study, hence, is
to explore whether an oxidative stress biomarker, malondialdehyde
(MDA) in the nasal fluid, has the potential to aid personalized asthma
control. In a panel study of 43 asthmatic children, 5–13 years
old, each child was measured 4 times with a 2-week interval between
consecutive clinic visits. At each visit, nasal fluid and urine samples
were collected, and fractional exhaled nitric oxide (FeNO) was measured
as a biomarker of pulmonary inflammation. In addition to nasal MDA,
urinary MDA and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were measured
as biomarkers of systemic oxidative stress. We also assessed asthma
symptoms using the Childhood Asthma-Control Test (C-ACT). We found
that interquartile range (IQR) increases in 24 h average personal
PM2.5 exposure (22.2–33.5 μg/m3), estimated 0 to 5 days prior to a clinic visit, were associated
with increased nasal MDA concentrations by 38.6–54.9%. Similarly,
IQR increases in 24 h average personal O3 exposure (7.7–8.2
ppb) estimated 2 to 4 days prior were associated with increased nasal
MDA by 22.1–69.4%. Only increased PM2.5 exposure
was associated with increased FeNO. Increased nasal MDA concentration
was associated with decreased total and individual C-ACT scores, indicating
worsening of asthma symptoms. However, no significant associations
were observed between urinary MDA or 8-OHdG and C-ACT scores. The
results confirm that oxidative stress plays an important role in linking
air pollution exposure and adverse respiratory health effects. These
findings support that MDA in the nasal fluid may serve as a useful
biomarker for monitoring asthma status, especially in relation to
PM2.5 and O3 exposures, two known risk factors
of asthma exacerbation.